BRPI0611455A2 - diaril-purinas, azapurinas e deazapurinas como inibidores não nucleosìdicos da transcriptase reversa para tratamento de hiv - Google Patents
diaril-purinas, azapurinas e deazapurinas como inibidores não nucleosìdicos da transcriptase reversa para tratamento de hiv Download PDFInfo
- Publication number
- BRPI0611455A2 BRPI0611455A2 BRPI0611455-5A BRPI0611455A BRPI0611455A2 BR PI0611455 A2 BRPI0611455 A2 BR PI0611455A2 BR PI0611455 A BRPI0611455 A BR PI0611455A BR PI0611455 A2 BRPI0611455 A2 BR PI0611455A2
- Authority
- BR
- Brazil
- Prior art keywords
- formula
- methyl
- benzyl
- cyclopropyl
- original document
- Prior art date
Links
- -1 diaryl purines Chemical class 0.000 title claims description 155
- 238000011282 treatment Methods 0.000 title abstract description 9
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 title abstract description 4
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 80
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 34
- 229910052801 chlorine Inorganic materials 0.000 claims description 31
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 22
- 229910052794 bromium Inorganic materials 0.000 claims description 22
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 20
- 229910052731 fluorine Inorganic materials 0.000 claims description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 2
- 125000000565 sulfonamide group Chemical group 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 229910052720 vanadium Inorganic materials 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 230000036436 anti-hiv Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 188
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 102
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 94
- 239000000243 solution Substances 0.000 description 94
- 235000019439 ethyl acetate Nutrition 0.000 description 80
- 239000000203 mixture Substances 0.000 description 69
- 239000011541 reaction mixture Substances 0.000 description 69
- 239000012267 brine Substances 0.000 description 54
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 54
- 238000006243 chemical reaction Methods 0.000 description 53
- 239000011734 sodium Substances 0.000 description 53
- 239000007787 solid Substances 0.000 description 51
- 239000000047 product Substances 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 34
- 239000012044 organic layer Substances 0.000 description 29
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- 238000004587 chromatography analysis Methods 0.000 description 23
- 239000000741 silica gel Substances 0.000 description 23
- 229910002027 silica gel Inorganic materials 0.000 description 23
- 239000000725 suspension Substances 0.000 description 23
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 22
- 239000005457 ice water Substances 0.000 description 21
- 239000012043 crude product Substances 0.000 description 20
- 229910052786 argon Inorganic materials 0.000 description 17
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 16
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 15
- 238000010898 silica gel chromatography Methods 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- YBAZINRZQSAIAY-UHFFFAOYSA-N 4-aminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1 YBAZINRZQSAIAY-UHFFFAOYSA-N 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 12
- 238000012746 preparative thin layer chromatography Methods 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 208000031886 HIV Infections Diseases 0.000 description 10
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 10
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 9
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- VHHSKDOVZHJECP-UHFFFAOYSA-N 4-cyclopropyl-2,6-dimethylphenol Chemical compound CC1=C(O)C(C)=CC(C2CC2)=C1 VHHSKDOVZHJECP-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 239000012414 tert-butyl nitrite Substances 0.000 description 5
- GTJHDGVPBSHFSU-UHFFFAOYSA-N 9-deazaguanine Chemical compound O=C1NC(N)=NC2=CC=N[C]21 GTJHDGVPBSHFSU-UHFFFAOYSA-N 0.000 description 4
- BLDVQELWSKXYEB-UHFFFAOYSA-N C(C1=CC=CC=C1)C1C(=CC(=N1)Cl)Cl Chemical compound C(C1=CC=CC=C1)C1C(=CC(=N1)Cl)Cl BLDVQELWSKXYEB-UHFFFAOYSA-N 0.000 description 4
- 229940124821 NNRTIs Drugs 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 3
- BPRYUXCVCCNUFE-UHFFFAOYSA-N 2,4,6-trimethylphenol Chemical compound CC1=CC(C)=C(O)C(C)=C1 BPRYUXCVCCNUFE-UHFFFAOYSA-N 0.000 description 3
- WFYGXOWFEIOHCZ-UHFFFAOYSA-N 4-hydroxy-3,5-dimethylbenzonitrile Chemical compound CC1=CC(C#N)=CC(C)=C1O WFYGXOWFEIOHCZ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229960002814 rilpivirine Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- PKANQZUPJCMBAK-UHFFFAOYSA-N 2,4,6-trimethylbenzenethiol Chemical compound CC1=CC(C)=C(S)C(C)=C1 PKANQZUPJCMBAK-UHFFFAOYSA-N 0.000 description 2
- PEDNLSVBZKUELM-UHFFFAOYSA-N 2-chloro-6-(4-cyclopropyl-2,6-dimethylphenoxy)-7h-purine Chemical compound C=1C(C)=C(OC=2C=3N=CNC=3N=C(Cl)N=2)C(C)=CC=1C1CC1 PEDNLSVBZKUELM-UHFFFAOYSA-N 0.000 description 2
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 2
- WHXOPNIRPCESAB-UHFFFAOYSA-N 4-[[6-(4-cyclopropyl-2,6-dimethylphenoxy)-7h-purin-2-yl]amino]benzonitrile Chemical compound CC1=CC(C2CC2)=CC(C)=C1OC(C=1N=CNC=1N=1)=NC=1NC1=CC=C(C#N)C=C1 WHXOPNIRPCESAB-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229910004809 Na2 SO4 Inorganic materials 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FAPDDOBMIUGHIN-UHFFFAOYSA-K antimony trichloride Chemical compound Cl[Sb](Cl)Cl FAPDDOBMIUGHIN-UHFFFAOYSA-K 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000006193 diazotization reaction Methods 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 2
- 229960002049 etravirine Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 2
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- GASZMAQKCBQIQS-UHFFFAOYSA-N (4-bromo-2,6-dimethylphenoxy)-tert-butyl-dimethylsilane Chemical compound CC1=CC(Br)=CC(C)=C1O[Si](C)(C)C(C)(C)C GASZMAQKCBQIQS-UHFFFAOYSA-N 0.000 description 1
- MUWPKXVVEOGKNO-UHFFFAOYSA-N 1-(4-hydroxy-3,5-dimethylphenyl)ethanone Chemical compound CC(=O)C1=CC(C)=C(O)C(C)=C1 MUWPKXVVEOGKNO-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- KWVPRPSXBZNOHS-UHFFFAOYSA-N 2,4,6-Trimethylaniline Chemical compound CC1=CC(C)=C(N)C(C)=C1 KWVPRPSXBZNOHS-UHFFFAOYSA-N 0.000 description 1
- SWELIMKTDYHAOY-UHFFFAOYSA-N 2,4-diamino-6-hydroxypyrimidine Chemical compound NC1=CC(=O)N=C(N)N1 SWELIMKTDYHAOY-UHFFFAOYSA-N 0.000 description 1
- LXYIYVMDJNSLPQ-UHFFFAOYSA-N 2,6-diamino-2,3-dihydro-1h-pyrimidin-4-one Chemical compound NC1NC(N)=CC(=O)N1 LXYIYVMDJNSLPQ-UHFFFAOYSA-N 0.000 description 1
- RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7h-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 description 1
- FNORUNUDZNWQFF-UHFFFAOYSA-N 2,6-dimethyl-4-nitrophenol Chemical compound CC1=CC([N+]([O-])=O)=CC(C)=C1O FNORUNUDZNWQFF-UHFFFAOYSA-N 0.000 description 1
- QPLKLVBUTSWJAA-UHFFFAOYSA-N 2-(pyrimidin-2-ylamino)benzonitrile Chemical compound N#CC1=CC=CC=C1NC1=NC=CC=N1 QPLKLVBUTSWJAA-UHFFFAOYSA-N 0.000 description 1
- PFTYCGMGNJVFIX-UHFFFAOYSA-N 2-amino-6-methyl-5-nitro-1h-pyrimidin-4-one Chemical compound CC=1NC(N)=NC(=O)C=1[N+]([O-])=O PFTYCGMGNJVFIX-UHFFFAOYSA-N 0.000 description 1
- WBPSQCNALROVPK-UHFFFAOYSA-N 2-benzyl-5-fluoro-3-(2,4,6-trimethylphenyl)sulfanyl-2H-pyrrole Chemical compound CC1=CC(C)=CC(C)=C1SC1=CC(F)=NC1CC1=CC=CC=C1 WBPSQCNALROVPK-UHFFFAOYSA-N 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- ADORQPCTHAPTTG-UHFFFAOYSA-N 3,5-dichloro-2-methyl-2H-pyrrole Chemical compound ClC1=NC(C(=C1)Cl)C ADORQPCTHAPTTG-UHFFFAOYSA-N 0.000 description 1
- YFKRLZLGVDDKAL-UHFFFAOYSA-N 3,5-dimethylbenzonitrile Chemical compound CC1=CC(C)=CC(C#N)=C1 YFKRLZLGVDDKAL-UHFFFAOYSA-N 0.000 description 1
- SCNPUDCZXNUNQZ-UHFFFAOYSA-N 4-(furan-2-yl)-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1=CC(OC)=CC=C1CN1C2=NC=NC(C=3OC=CC=3)=C2C=N1 SCNPUDCZXNUNQZ-UHFFFAOYSA-N 0.000 description 1
- CUKNKVIGQMOCLG-UHFFFAOYSA-N 4-[(2-methyl-2H-pyrrol-5-yl)amino]benzonitrile Chemical compound C(#N)C1=CC=C(C=C1)NC1=NC(C=C1)C CUKNKVIGQMOCLG-UHFFFAOYSA-N 0.000 description 1
- LCWKIAHCEIHHJE-UHFFFAOYSA-N 4-[(dimethylamino)methyl]-2,6-dimethylphenol Chemical compound CN(C)CC1=CC(C)=C(O)C(C)=C1 LCWKIAHCEIHHJE-UHFFFAOYSA-N 0.000 description 1
- BQXWCIIMPBSHIU-UHFFFAOYSA-N 5-chloro-2-methyl-3-(2,4,6-trimethylphenoxy)-2H-pyrrole Chemical compound CC1N=C(Cl)C=C1OC1=C(C)C=C(C)C=C1C BQXWCIIMPBSHIU-UHFFFAOYSA-N 0.000 description 1
- DLOJCIUPXOPVFG-UHFFFAOYSA-N 5-chloro-3-(4-cyclopropyl-2,6-dimethylphenoxy)-2H-pyrrole Chemical compound ClC1=NCC(=C1)OC1=C(C=C(C=C1C)C1CC1)C DLOJCIUPXOPVFG-UHFFFAOYSA-N 0.000 description 1
- DGNPSLFLQSTTDQ-UHFFFAOYSA-N 6-(4-cyclopropyl-2,6-dimethylphenoxy)-7H-purine Chemical compound C1(CC1)C1=CC(=C(OC2=C3N=CNC3=NC=N2)C(=C1)C)C DGNPSLFLQSTTDQ-UHFFFAOYSA-N 0.000 description 1
- XRCTVEFABOUQNI-UHFFFAOYSA-N 7-benzyl-2,6-dichloropurine Chemical compound C1=NC2=NC(Cl)=NC(Cl)=C2N1CC1=CC=CC=C1 XRCTVEFABOUQNI-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- DYGBVOGDAYTZFM-UHFFFAOYSA-N C(C1=CC=CC=C1)C1C=CC(=N1)F Chemical compound C(C1=CC=CC=C1)C1C=CC(=N1)F DYGBVOGDAYTZFM-UHFFFAOYSA-N 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- DHTKIRDQAQIVNK-UHFFFAOYSA-N C1=CC=C(C=C1)CC2C(=CC=N2)Cl Chemical compound C1=CC=C(C=C1)CC2C(=CC=N2)Cl DHTKIRDQAQIVNK-UHFFFAOYSA-N 0.000 description 1
- HGAQQPUPXVMMOV-UHFFFAOYSA-N CC1=CC(=C(C(=C1)C)OC2=CC=NC2CC3=CC=CC=C3)C Chemical compound CC1=CC(=C(C(=C1)C)OC2=CC=NC2CC3=CC=CC=C3)C HGAQQPUPXVMMOV-UHFFFAOYSA-N 0.000 description 1
- IBANHJNQPOPTOM-UHFFFAOYSA-N CC1=CC(=C(C(=C1)C)SC2=CC=NC2CC3=CC=CC=C3)C Chemical compound CC1=CC(=C(C(=C1)C)SC2=CC=NC2CC3=CC=CC=C3)C IBANHJNQPOPTOM-UHFFFAOYSA-N 0.000 description 1
- 125000006519 CCH3 Chemical group 0.000 description 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- VIOXRJKRKTUPKD-UHFFFAOYSA-N NC1=NC=CC1CC1=CC=CC=C1 Chemical compound NC1=NC=CC1CC1=CC=CC=C1 VIOXRJKRKTUPKD-UHFFFAOYSA-N 0.000 description 1
- 101150104269 RT gene Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- YQXCVAGCMNFUMQ-UHFFFAOYSA-N capravirine Chemical compound C=1C(Cl)=CC(Cl)=CC=1SC1=C(C(C)C)N=C(COC(N)=O)N1CC1=CC=NC=C1 YQXCVAGCMNFUMQ-UHFFFAOYSA-N 0.000 description 1
- 229950008230 capravirine Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- BYIHXUHOYZDNTR-UHFFFAOYSA-M chlorozinc(1+);cyclopropane Chemical compound [Cl-].[Zn+2].C1C[CH-]1 BYIHXUHOYZDNTR-UHFFFAOYSA-M 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- PHTXVQQRWJXYPP-UHFFFAOYSA-N ethyltrifluoromethylaminoindane Chemical compound C1=C(C(F)(F)F)C=C2CC(NCC)CC2=C1 PHTXVQQRWJXYPP-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- LFLZOWIFJOBEPN-UHFFFAOYSA-N nitrate, nitrate Chemical compound O[N+]([O-])=O.O[N+]([O-])=O LFLZOWIFJOBEPN-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- BPLGKNGGMMHXMK-UHFFFAOYSA-N tert-butyl-(4-cyclopropyl-2,6-dimethylphenoxy)-dimethylsilane Chemical compound CC1=C(O[Si](C)(C)C(C)(C)C)C(C)=CC(C2CC2)=C1 BPLGKNGGMMHXMK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67866705P | 2005-05-05 | 2005-05-05 | |
| US60/678,667 | 2005-05-05 | ||
| PCT/US2006/017677 WO2006122003A2 (en) | 2005-05-05 | 2006-05-05 | Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0611455A2 true BRPI0611455A2 (pt) | 2010-09-08 |
Family
ID=37397195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0611455-5A BRPI0611455A2 (pt) | 2005-05-05 | 2006-05-05 | diaril-purinas, azapurinas e deazapurinas como inibidores não nucleosìdicos da transcriptase reversa para tratamento de hiv |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8227601B2 (enExample) |
| EP (1) | EP1877411B9 (enExample) |
| JP (2) | JP5138585B2 (enExample) |
| CN (1) | CN101233135B (enExample) |
| AT (1) | ATE541848T1 (enExample) |
| AU (1) | AU2006244195B2 (enExample) |
| BR (1) | BRPI0611455A2 (enExample) |
| CA (1) | CA2607021C (enExample) |
| ES (1) | ES2380951T3 (enExample) |
| MX (1) | MX2007013715A (enExample) |
| WO (1) | WO2006122003A2 (enExample) |
| ZA (1) | ZA200709481B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2361835T3 (es) * | 2003-09-25 | 2011-06-22 | Janssen Pharmaceutica Nv | Derivados de purina inhibidores de la replicación del hiv. |
| ATE541848T1 (de) | 2005-05-05 | 2012-02-15 | Ardea Biosciences Inc | Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv |
| CN101611035A (zh) * | 2006-12-28 | 2009-12-23 | 大正制药株式会社 | 吡唑并嘧啶化合物 |
| EP2220091B1 (en) | 2007-12-14 | 2012-07-25 | Ardea Biosciences, Inc. | Reverse transcriptase inhibitors |
| UY31631A1 (es) | 2008-02-06 | 2009-09-30 | Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones | |
| WO2010111406A2 (en) * | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
| MX392130B (es) * | 2013-06-27 | 2025-03-21 | Janssen Sciences Ireland Uc | Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades. |
| SG11201607990QA (en) | 2014-04-25 | 2016-11-29 | Pfizer | Heteroaromatic compounds and their use as dopamine d1 ligands |
| US10913744B2 (en) | 2015-02-13 | 2021-02-09 | Dana-Farber Cancer Institute, Inc. | LRRK2 inhibitors and methods of making and using the same |
| CN106188060A (zh) * | 2015-04-29 | 2016-12-07 | 厦门大学 | 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用 |
| KR102048719B1 (ko) * | 2015-08-13 | 2019-11-26 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Irak4억제제 및 이의 용도 |
| CN106117242B (zh) * | 2016-06-27 | 2018-08-03 | 山东大学 | 四氢噻喃并嘧啶类衍生物及其制备方法与应用 |
| CN107793417B (zh) * | 2016-09-05 | 2020-06-09 | 复旦大学 | 吡咯并[2,3-d]嘧啶类化合物及其盐，及制备方法和药用用途 |
| CN106749266B (zh) * | 2016-11-14 | 2019-01-22 | 山东大学 | 吡咯并[2,3-d]嘧啶类化合物的高效制备方法 |
| TW202415645A (zh) | 2018-03-01 | 2024-04-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | ２，４－二胺基喹唑啉衍生物及其醫學用途 |
| CN111499639B (zh) * | 2019-01-31 | 2022-03-04 | 四川大学华西医院 | 嘧啶酮衍生物及其在制药中的应用 |
| US20230279006A1 (en) * | 2020-07-08 | 2023-09-07 | Klotho Therapeutics, Inc. | Novel compounds and methods for increasing klotho gene expression |
| EP4251613A4 (en) * | 2020-11-27 | 2024-11-20 | Allorion Therapeutics Inc. | AMINOHETEROARYL KINASE INHIBITORS |
| EP4707277A1 (en) * | 2023-05-04 | 2026-03-11 | Daewoong Pharmaceutical Co., Ltd. | Novel heterocyclic amine derivatives and pharmaceutical composition comprising same |
| US20250333424A1 (en) * | 2024-03-01 | 2025-10-30 | Gilead Sciences, Inc. | Antiviral compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ229453A (en) * | 1988-06-10 | 1991-08-27 | Univ Minnesota & Southern Rese | A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents |
| CA2349904A1 (en) | 1998-11-12 | 2000-05-18 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods relating thereto |
| US6414147B1 (en) * | 1998-12-23 | 2002-07-02 | Neurogen Corporation | 2-amino-9-alkylpurines: GABA brain receptor ligands |
| CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| YU25500A (sh) * | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| EP1597237B1 (en) | 2003-02-07 | 2016-07-27 | Janssen Pharmaceutica NV | Pyrimidine derivatives for the prevention of HIV infection |
| ES2361835T3 (es) * | 2003-09-25 | 2011-06-22 | Janssen Pharmaceutica Nv | Derivados de purina inhibidores de la replicación del hiv. |
| BRPI0517272A (pt) | 2004-10-29 | 2008-10-07 | Tibotec Pharm Ltd | derivados de pirimidina bicìclicos de inibição de hiv |
| ATE541848T1 (de) * | 2005-05-05 | 2012-02-15 | Ardea Biosciences Inc | Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv |
-
2006
- 2006-05-05 AT AT06759292T patent/ATE541848T1/de active
- 2006-05-05 CN CN2006800243079A patent/CN101233135B/zh not_active Expired - Fee Related
- 2006-05-05 US US11/919,786 patent/US8227601B2/en not_active Expired - Fee Related
- 2006-05-05 EP EP06759292A patent/EP1877411B9/en not_active Expired - Lifetime
- 2006-05-05 AU AU2006244195A patent/AU2006244195B2/en not_active Ceased
- 2006-05-05 MX MX2007013715A patent/MX2007013715A/es active IP Right Grant
- 2006-05-05 JP JP2008510307A patent/JP5138585B2/ja not_active Expired - Fee Related
- 2006-05-05 ES ES06759292T patent/ES2380951T3/es not_active Expired - Lifetime
- 2006-05-05 BR BRPI0611455-5A patent/BRPI0611455A2/pt not_active Application Discontinuation
- 2006-05-05 WO PCT/US2006/017677 patent/WO2006122003A2/en not_active Ceased
- 2006-05-05 CA CA2607021A patent/CA2607021C/en not_active Expired - Fee Related
-
2007
- 2007-11-02 ZA ZA200709481A patent/ZA200709481B/xx unknown
-
2012
- 2012-05-11 US US13/470,116 patent/US8354532B2/en not_active Expired - Fee Related
- 2012-06-26 JP JP2012143245A patent/JP2012188454A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2607021A1 (en) | 2006-11-16 |
| MX2007013715A (es) | 2008-01-28 |
| WO2006122003A3 (en) | 2007-01-04 |
| US8354532B2 (en) | 2013-01-15 |
| EP1877411B9 (en) | 2012-08-29 |
| JP5138585B2 (ja) | 2013-02-06 |
| JP2012188454A (ja) | 2012-10-04 |
| WO2006122003A2 (en) | 2006-11-16 |
| ZA200709481B (en) | 2008-11-26 |
| CN101233135A (zh) | 2008-07-30 |
| ATE541848T1 (de) | 2012-02-15 |
| US8227601B2 (en) | 2012-07-24 |
| ES2380951T3 (es) | 2012-05-21 |
| AU2006244195A1 (en) | 2006-11-16 |
| US20120226037A1 (en) | 2012-09-06 |
| ES2380951T9 (es) | 2012-12-21 |
| EP1877411B1 (en) | 2012-01-18 |
| CN101233135B (zh) | 2012-10-03 |
| EP1877411A2 (en) | 2008-01-16 |
| AU2006244195B2 (en) | 2012-03-15 |
| US20090124802A1 (en) | 2009-05-14 |
| EP1877411A4 (en) | 2008-10-22 |
| CA2607021C (en) | 2013-10-29 |
| JP2008540454A (ja) | 2008-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8354532B2 (en) | Pyrrolo [2,3-D] pyrimidines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV | |
| US7439240B2 (en) | Purine-or pyrrolol[2,3-d]pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity | |
| JP2815617B2 (ja) | 縮合ピリミジン誘導体およびその製造方法 | |
| US3211731A (en) | Pyrazolo-pyrimidines and process for preparing same | |
| Li et al. | Synthesis and Anti‐tumor Activities of Novel Pyrazolo [1, 5‐a] pyrimidines | |
| JP2006521398A (ja) | ＴＧＦβの二−環式ピリミジン阻害剤 | |
| AU2010201160A1 (en) | Bicyclic pyrimidinones and uses thereof | |
| CN1200374A (zh) | 玻连蛋白受体拮抗剂,其制备和用途 | |
| US20020183375A1 (en) | Imidazolyl derivatives as corticotropin releasing factor inhibitors | |
| AU2010218781A1 (en) | Pyrimidopyrimidoindazole derivative | |
| US6387912B1 (en) | Utilization of pyrimidine derivatives for preventing and treating cerebral ischaemia | |
| LV10717B (en) | Triazolopyrimidine derivatives, method for preparation thereof, pharmaceutical compositions containing them, methods for preparing these compositions | |
| KOSASAYAMA et al. | Cyclic Guanidines. VI. Synthesis of Hypoglycemic Tricyclic Guanidines | |
| US3320256A (en) | Fluorinated imidazoo[1, 2-c]pyrimidines and pyrimido[1, 2-c]pyrimidines | |
| JPH0559056A (ja) | キサンチン誘導体 | |
| CA2307080C (en) | Process for preparing 8-cyclopentyl-6-ethyl-3-¬substituted|-5,8-dihydro-4h-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein | |
| Coburn et al. | Mesoionic purinone analogs. VIII. Synthesis and properties of mesoionic 5‐substituted‐6‐methylimidazo [1, 2‐c] pyrimidine‐2, 7‐diones | |
| Remennikov et al. | An Unexpected Pyrimidine Ring Transformations in the Reaction of 4‐aryl‐5‐nitro‐6‐bromomethylpyrimidin‐2 (1H)‐ones with Anilines | |
| CS788487A2 (en) | Method of triazole's condensed cyclic derivatives production | |
| ES2977643T3 (es) | Proceso para fabricar inhibidores de la transcriptasa inversa | |
| AU2012203082A1 (en) | Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV | |
| Ryabova et al. | Reduction of 12-acetylaminoindolo [1, 2-c] quinazolines. Preparation of derivatives of the new heterocyclic system indolo [3, 2-d][1, 3] benzodiazepine | |
| JPS61263977A (ja) | ジヒドロイミダゾ〔１，２−ａ〕ピリミジン誘導体 | |
| MX2007002450A (es) | Pirimidinas biciclicas inhibidoras del virus de la hepatitis c. | |
| KR20010081096A (ko) | 이환 질소 헤테로사이클 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: ARDEA BIOSCIENCES, INC. (US) Free format text: ENDERECO DO DEPOSITANTE ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110130903/RJ DE 19/12/2011. |
|
| B25G | Requested change of headquarter approved |
Owner name: ARDEA BIOSCIENCES, INC. (US) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 487/04 , C07D 473/30 , C07D 473/34 , C07D 473/38 Ipc: C07D 487/04 (2006.01), C07D 473/30 (2006.01), C07D |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |